In a follow-up analysis to the pivotal TOPAZ-1 study, which established the combination therapy of durvalumab (an immunotherapy drug) plus gemcitabine and cisplatin (GemCis, chemotherapy drugs) as the first-line treatment for people with advanced bilia…
Researchers have developed a new gene-editing platform that will enable safer and more effective T cell–based immunotherapies to treat cancer.
Breast cancer is the most commonly diagnosed cancer among women worldwide and represents a major public health concern due to its high incidence and significant mortality rates. In the U.S. alone, approximately 297,790 new cases of invasive breast canc…
Researchers at University of Tsukuba have identified multiple T-cell subtypes with unique characteristics in follicular lymphoma, a prevalent type of blood cancer. These T cells regulate the proliferation and apoptosis of tumor cells and significantly …
Powerful new immunotherapies are offering fresh hope for patients with many different types of cancer.
Teclistamab-cqyv is a T-cell-engaging bispecific antibody that targets multiple myeloma cells via the B-cell maturation antigen (BCMA) receptor. It received accelerated approval in 2022 for patients treated with four or more lines of prior therapy base…
The herpes simplex virus type 1 (HSV-1), which affects almost two‑thirds of the world’s population and is generally associated with oral herpes, may cause painful cold sores or fever blisters around the mouth.
Preliminary results of an observational clinical trial underway at Roswell Park Comprehensive Cancer Center are shedding light on why some patients with an aggressive form of metastatic breast cancer fare better than others after receiving standard tre…
Targeted cancer drugs known as CDK4/6 inhibitors have improved outcomes for patients with advanced or metastatic HR+/HER2- breast cancer, but many patients still eventually relapse and become resistant to therapy. New research co-headed by a Fox Chase …
T-cell acute lymphoblastic leukemia (T-ALL) is a highly aggressive form of blood cancer that can occur in both children and adults. It is characterized by failures in the maturation of T-lymphocytes, key immune cells involved in the defense against inf…
